Effect of Buspirone on Withdrawal Symptoms Associated With Smoking Cessation

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background.—Preliminary information suggests that buspirone hydrochloride ameliorates symptoms of nicotine withdrawal. In a double-blind, randomized, placebocontrolled trial, we determined the effects of buspirone on the withdrawal symptoms associated with smoking cessation in 40 long-term cigarette smokers. Methods.—Subjects Subjects were randomized to 4 weeks of treatment with either buspirone (n = 20) or placebo (n = 20). Subjects were instructed to maintain their usual cigarette intake during the first 21 days of treatment and to cease smoking on day 22 of treatment. Withdrawal symptoms were subjectively rated before and during smoking cessation. Results.—Before smoking cessation, there were no significant differences in the intensity of any withdrawal symptom between the buspirone- and placebo-treated subjects, with the exception of a significantly higher rating for drowsiness in the buspirone group. During the smoking cessation period, the ratings for craving, anxiety, irritability, restlessness, and sadness were significantly lower in the buspirone group than the placebo group. there were no significant differences between the groups in their ratings for hunger, inability to concentrate, or drowsiness. Fifteen buspirone-treated subjects and nine placebo-treated subjects were able to abstain from cigarettes during the entire 7-day smoking cessation period. No subject dropped out of the study for perceived drug side effects. Eight buspironetreated subjects and five placebo-treated subjects reported side effects, all of which were mild. Conclusions.—Buspirone ameliorated most of the shortterm withdrawal symptoms associated with smoking cessation. Further controlled studies will be needed to define the benefit in smoking cessation.

Original languageEnglish
Pages (from-to)350-352
Number of pages3
JournalArchives of Internal Medicine
Volume152
Issue number2
DOIs
StatePublished - 1992

Fingerprint

Buspirone
Substance Withdrawal Syndrome
Smoking Cessation
Placebos
Tobacco Products
Sleep Stages
Psychomotor Agitation
Hunger
Drug-Related Side Effects and Adverse Reactions
Nicotine
Therapeutics
Anxiety
Smoking

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Effect of Buspirone on Withdrawal Symptoms Associated With Smoking Cessation. / Hilleman, Daniel E.; Mohiuddin, Syed M.; Del Core, Michael; Sketch, Michael H.

In: Archives of Internal Medicine, Vol. 152, No. 2, 1992, p. 350-352.

Research output: Contribution to journalArticle

@article{ca7a5c9c0fd14299a946946990f969a6,
title = "Effect of Buspirone on Withdrawal Symptoms Associated With Smoking Cessation",
abstract = "Background.—Preliminary information suggests that buspirone hydrochloride ameliorates symptoms of nicotine withdrawal. In a double-blind, randomized, placebocontrolled trial, we determined the effects of buspirone on the withdrawal symptoms associated with smoking cessation in 40 long-term cigarette smokers. Methods.—Subjects Subjects were randomized to 4 weeks of treatment with either buspirone (n = 20) or placebo (n = 20). Subjects were instructed to maintain their usual cigarette intake during the first 21 days of treatment and to cease smoking on day 22 of treatment. Withdrawal symptoms were subjectively rated before and during smoking cessation. Results.—Before smoking cessation, there were no significant differences in the intensity of any withdrawal symptom between the buspirone- and placebo-treated subjects, with the exception of a significantly higher rating for drowsiness in the buspirone group. During the smoking cessation period, the ratings for craving, anxiety, irritability, restlessness, and sadness were significantly lower in the buspirone group than the placebo group. there were no significant differences between the groups in their ratings for hunger, inability to concentrate, or drowsiness. Fifteen buspirone-treated subjects and nine placebo-treated subjects were able to abstain from cigarettes during the entire 7-day smoking cessation period. No subject dropped out of the study for perceived drug side effects. Eight buspironetreated subjects and five placebo-treated subjects reported side effects, all of which were mild. Conclusions.—Buspirone ameliorated most of the shortterm withdrawal symptoms associated with smoking cessation. Further controlled studies will be needed to define the benefit in smoking cessation.",
author = "Hilleman, {Daniel E.} and Mohiuddin, {Syed M.} and {Del Core}, Michael and Sketch, {Michael H.}",
year = "1992",
doi = "10.1001/archinte.1992.00400140096021",
language = "English",
volume = "152",
pages = "350--352",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Effect of Buspirone on Withdrawal Symptoms Associated With Smoking Cessation

AU - Hilleman, Daniel E.

AU - Mohiuddin, Syed M.

AU - Del Core, Michael

AU - Sketch, Michael H.

PY - 1992

Y1 - 1992

N2 - Background.—Preliminary information suggests that buspirone hydrochloride ameliorates symptoms of nicotine withdrawal. In a double-blind, randomized, placebocontrolled trial, we determined the effects of buspirone on the withdrawal symptoms associated with smoking cessation in 40 long-term cigarette smokers. Methods.—Subjects Subjects were randomized to 4 weeks of treatment with either buspirone (n = 20) or placebo (n = 20). Subjects were instructed to maintain their usual cigarette intake during the first 21 days of treatment and to cease smoking on day 22 of treatment. Withdrawal symptoms were subjectively rated before and during smoking cessation. Results.—Before smoking cessation, there were no significant differences in the intensity of any withdrawal symptom between the buspirone- and placebo-treated subjects, with the exception of a significantly higher rating for drowsiness in the buspirone group. During the smoking cessation period, the ratings for craving, anxiety, irritability, restlessness, and sadness were significantly lower in the buspirone group than the placebo group. there were no significant differences between the groups in their ratings for hunger, inability to concentrate, or drowsiness. Fifteen buspirone-treated subjects and nine placebo-treated subjects were able to abstain from cigarettes during the entire 7-day smoking cessation period. No subject dropped out of the study for perceived drug side effects. Eight buspironetreated subjects and five placebo-treated subjects reported side effects, all of which were mild. Conclusions.—Buspirone ameliorated most of the shortterm withdrawal symptoms associated with smoking cessation. Further controlled studies will be needed to define the benefit in smoking cessation.

AB - Background.—Preliminary information suggests that buspirone hydrochloride ameliorates symptoms of nicotine withdrawal. In a double-blind, randomized, placebocontrolled trial, we determined the effects of buspirone on the withdrawal symptoms associated with smoking cessation in 40 long-term cigarette smokers. Methods.—Subjects Subjects were randomized to 4 weeks of treatment with either buspirone (n = 20) or placebo (n = 20). Subjects were instructed to maintain their usual cigarette intake during the first 21 days of treatment and to cease smoking on day 22 of treatment. Withdrawal symptoms were subjectively rated before and during smoking cessation. Results.—Before smoking cessation, there were no significant differences in the intensity of any withdrawal symptom between the buspirone- and placebo-treated subjects, with the exception of a significantly higher rating for drowsiness in the buspirone group. During the smoking cessation period, the ratings for craving, anxiety, irritability, restlessness, and sadness were significantly lower in the buspirone group than the placebo group. there were no significant differences between the groups in their ratings for hunger, inability to concentrate, or drowsiness. Fifteen buspirone-treated subjects and nine placebo-treated subjects were able to abstain from cigarettes during the entire 7-day smoking cessation period. No subject dropped out of the study for perceived drug side effects. Eight buspironetreated subjects and five placebo-treated subjects reported side effects, all of which were mild. Conclusions.—Buspirone ameliorated most of the shortterm withdrawal symptoms associated with smoking cessation. Further controlled studies will be needed to define the benefit in smoking cessation.

UR - http://www.scopus.com/inward/record.url?scp=0026553158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026553158&partnerID=8YFLogxK

U2 - 10.1001/archinte.1992.00400140096021

DO - 10.1001/archinte.1992.00400140096021

M3 - Article

VL - 152

SP - 350

EP - 352

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 2

ER -